In conclusion, the strength of our study stands in the use of complementary approaches (in vivo, in vitro, and human brain samples) to characterize ASIC2 contribution in MS pathophysiology and the integration of different evidences from experimental data on the role of ASIC2 in MS, which was previously limited to ASIC1. This evidence concerns the gene ASIC1 and myeloid sarcoma.